Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.
You may also be interested in...
Novartis Seeks European Approval For Galvus
The novel type 2 diabetes therapy has a likely November user fee date in the U.S.
Novartis Seeks European Approval For Galvus
The novel type 2 diabetes therapy has a likely November user fee date in the U.S.
Diabetes Prevention Drugs Will Be Addressed In FDA Guidance
Metabolic syndrome may also be discussed in draft document expected to be out by year-end.